BETAHEALTH ETF UNITS [DRUG]
Betashare Global Healthcare ETF -Currency Hedged (DRUG) provides simple, cost-effective and transparent exposure to the largest companies in the global healthcare sector. The Fund aims to track the performance of an index (before fees and expenses) which provides exposure to the performance of the largest global healthcare companies by market capitalization (excluding companies in Australia), hedged into Australian dollars.
Buy Australian shares starting with DRUG. Invest today with a CHESS-sponsored broker!
What is DRUG stock?
DRUG is an exchange-traded fund that invests in large-cap healthcare companies outside of Australia, both directly and through foreign currency forward contracts.
Also known as BetaShares Global Healthcare ETF - Currency Hedged, DRUG is actively managed by BetaShares Capital Limited. It seeks to replicate the behaviour of the Nasdaq Global ex-Australia Healthcare Hedged AUD Index by investing in companies as per their weight in the index. DRUG’s returns are hedged to the Australian dollar.
Why is DRUG a currency-hedged ETF?
DRUG ETF is denominated in Australian dollars but equities within the fund are in foreign currencies.
By currency hedging, BetaShares locks down a set exchange rate for the future and lowers the effects and risks of exchange rate fluctuations on investments within DRUG.
How do I buy DRUG stock?
Stake offers a quick and easy way to purchase the DRUG ETF – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.
Stake is a CHESS sponsored broker, meaning that when you buy ASX shares, you get a HIN (Holder Identification Number) and stocks are held in your name.
With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding DRUG, sign up today.
Which stocks are in the DRUG ETF?
73.9% of DRUG is allocated to American healthcare stocks. Swiss, British, Japanese and Danish healthcare companies are also sizeable allocations at 9.4%, 4.9%, 3.3% and 3.2%, respectively.
Some of DRUG’s most prominent holdings include UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Pfizer Inc. (PFE), Roche (ROG), Eli Lilly & Company (LLY), Thermo Fisher Scientific (TMO), AstraZeneca (AZN), Novo Nordisk (NOVO-B) and Takeda Pharmaceutical Company (4502).
For a complete list of DRUG’s current holdings, click here.
Does DRUG pay a distribution?
Yes. As of 31 March 2022, DRUG stock’s distribution yield is 4.7%.
In FY2021, Betashares paid out a total of A$0.36644 per share. Historically, distributions have been paid twice a year, usually in January and July.
Is DRUG a good buy?
DRUG may be an appropriate buy for investors seeking quick, simple and cost-effective access to the world’s biggest healthcare companies. By purchasing DRUG, investors do not need to purchase individual healthcare stocks.
ETFs are usually considered long-term passive investments and the DRUG ETF is no exception. The fund has a low management cost of 0.57% p.a. In FY2021, the DRUG stock price achieved 22.34% growth.
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake AUS
- Deposit directly into your Stake wallet and you're ready to invest in DRUG
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.